Pfizer Articles

PFIZER APPOINTMENT

3 August 1992

US PRICE MODERATION "VARIES BY COMPANY"

3 August 1992

GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs

3 August 1992

US PRICE MODERATION "VARIES BY COMPANY"

3 August 1992

GLAXO PROSPECTS GLOOM: FACT OR FICTION?

3 August 1992

Pfizer names new president

6 July 1992

DERMATOLOGISTS HIGHLIGHT SPORANOX

29 June 1992

US PHARMA INDEX LAUNCHED

29 June 1992

advance in renin research

15 June 1992

US COMPANY NEWS IN BRIEF

15 June 1992

Pharmarar reaches agreement

8 June 1992

Maxaquin to be copromoted

8 June 1992

ZANTAC TOPS MAIL ORDER SALES IN USA

8 June 1992

B-MS WARNING WITH EARNINGS FORECAST CUT

8 June 1992

New York: Stock Commentary

8 June 1992

product liability and medicines

8 June 1992

Rx-to-OTC switch - key to OTC market in USA By Mick Maroney, manager, North

1 June 1992

PFIZER'S DIFLUCAN LAUNCHED IN NIGERIA

25 May 1992

ASTRA'S PLENDIL HEADING FOR CHF INDICATION

25 May 1992

STOCK MARKET COMMENTARY: NEW YORK

25 May 1992

US DRUG FIRMS' PUERTO RICO TAX CREDITS

25 May 1992

SYNTHELABO INTENDS TO UP INTERNATIONAL STATUS

25 May 1992

TLC CHAIRMAN LOOKS BACK ON 1991

18 May 1992

JAPAN SUBSIDS DO WELL FOR MNCs

18 May 1992

FORTHCOMING MEETINGS

18 May 1992

STOCK MARKET COMMENTARY: NEW YORK

11 May 1992

IMPLICATIONS OF TECHNOLOGY

11 May 1992

PHASE II INTERIM RESULTS OF TLC D-99

4 May 1992

PFIZER RESEARCH SPENDING IN 1992

4 May 1992

GOOD 1st QTRs for ALZA, IMMUNEX AND MYLAN

4 May 1992

STOCK MARKET COMMENTARY: NEW YORK

4 May 1992

US FDA APPROVABLE LETTER TO PFIZER

4 May 1992

PFIZER NAMES VISINE AGENT

27 April 1992

US DRUGMAKERS TAX PENALIZATION

27 April 1992

IMPROVEMENTS IN 1ST QTR FOR US FIRMS

20 April 1992

STOCK MARKET COMMENTARY: NEW YORK

13 April 1992

US NEW PRESCRIPTI0N DRUG SALES IN 1991

13 April 1992

DEPRESSION: THE COST TO SOCIETY

6 April 1992

STOCK MARKET COMMENTARY: NEW YORK

6 April 1992

INDIAN IBUPROFEN CHARGE DROPPED

6 April 1992

NEW US IMPLANT REGULATIONS

6 April 1992

PFIZER'S DIFLUCAN

6 April 1992

PFIZER'S DIFLUCAN

6 April 1992

NEW US IMPLANT REGULATIONS

6 April 1992

INDIAN IBUPROFEN CHARGE DROPPED

6 April 1992

STOCK MARKET COMMENTARY: NEW YORK

6 April 1992

DEPRESSION: THE COST TO SOCIETY

6 April 1992

FDA SAYS PFIZER MUST WARN PATIENTS

23 March 1992

US PRESCRIPTION PRICES UP 8.1%IN 1991

23 March 1992

STOCK MARKET COMMENTARY: NEW YORK

23 March 1992

DANISH COMPLAIN OVER GLAXO PRICING

23 March 1992

INDUSTRY VIEWS US FDA CME GUIDE

16 March 1992

ABPI RULES ON TV CLAIMS AGAINST ROUSSEL

16 March 1992

STOCK MARKET COMMENTARY: NEW YORK

16 March 1992

XOMA MERGER RUMORS

16 March 1992

VOLUME GROWTH FOR US DRUGMAKERS

9 March 1992

CAL BIO FOURTH QUARTER LOSS

9 March 1992

PFIZER IN JAPANESE ACQUISITION

9 March 1992

STOCK MARKET COMMENTARY: NEW YORK

9 March 1992

PFIZER INVESTS IN NEUROGEN RESEARCH

17 February 1992

US GENERIC DRUG MARKET TO 1995

17 February 1992

NEW CHEMICAL ENTITIES UPDATE FOR 1991

10 February 1992

PFIZER PLANS NEW UNIT IN USA

10 February 1992

MERCK'S PROSCAR NEARING US APPROVAL

10 February 1992

B-M SQUIBB GIVES HEART DRUGS FREE TO POOR

3 February 1992

GOOD 1991 RESULTS FOR MERCK AND FOREST LABS

3 February 1992

PFIZER CHAIRMAN RETIRES

3 February 1992

PFIZER AGREEMENT ON SHILEY VALVE

3 February 1992

GUT HORMONE COULD DISPLACE INSULIN

27 January 1992

STOCK MARKET COMMENTARY: NEW YORK

27 January 1992

ALZA PRODUCT PROMOTIONS

20 January 1992

STOCK MARKET COMMENTARY: NEW YORK

20 January 1992

AMERICAN HOME AND ONCOGENE SCI DEAL

20 January 1992

US FDA BEATS 1990 DRUG APPROVALS IN 1991

13 January 1992

DRUG FIRMS ARE STOCK MARKET DARLINGS

13 January 1992

PFIZER'S DIFLUCAN & AIDS-ASSOCIATED CM

13 January 1992

STOCK MARKET COMMENTARY: NEW YORK

13 January 1992

ANALGESICS IN THE USA -- AN OPEN DOOR FOR P&G?

6 January 1992

FEWER ACQUISITIONS AND MERGERS IN 1991

6 January 1992

APPOINTMENTS AT PFIZER

6 January 1992

PFIZER TO SELL HEART DEVICE BUSINESS

6 January 1992

YEAR-END FDA APPROVALS

6 January 1992

Axitinib fails pancreatic cancer; Pfizer drops 3.6%

Canadian patent reform could hit generics